MapLight Therapeutics, Inc. (MPLT)
| Market Cap | 1.34B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -161.15M |
| Shares Out | 44.02M |
| EPS (ttm) | -18.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 113,568 |
| Open | 29.81 |
| Previous Close | 30.64 |
| Day's Range | 28.58 - 30.95 |
| 52-Week Range | 12.24 - 33.28 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 32.67 (+7.26%) |
| Earnings Date | May 28, 2026 |
About MPLT
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company’s products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer’s disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson’s disease; ML-055 for the treatment of neuropsychiatric co... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for MPLT stock is "Strong Buy." The 12-month stock price target is $32.67, which is an increase of 7.26% from the latest price.
News
MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst
Needham initiated coverage on MapLight Therapeutics Inc. (NASDAQ: MPLT). The company, which is focused on central nervous system disorders, debuted on NASDAQ in October 2025 and raised $296.3 million ...
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering...
MapLight Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO and BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor c...
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Ph...
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis
SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Tr...
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies
SAN FRANCISCO and BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- SandboxAQ and MapLight Therapeutics, Inc. (Nasdaq: MPLT) announced today that the companies have entered into a strategic collaboration to d...
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026 Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer's disease psychosis e...
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO and BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitati...
MapLight Therapeutics valued at $787 million as shares jump in Nasdaq debut
Shares of MapLight Therapeutics opened 11.8% above their offer price in their Nasdaq debut on Monday, giving the drug developer a $787 million valuation.
MapLight Therapeutics Announces Pricing of Initial Public Offering
SAN FRANCISCO and BOSTON, Oct. 26, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitati...
MapLight Therapeutics IPO Registration Document (S-1)
MapLight Therapeutics has filed to go public with an IPO on the NASDAQ.
CNS disorder biotech MapLight Therapeutics files for a $100 million IPO
MapLight Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric and CNS disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.